Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
18 August 2021 | Story André Damons | Photo André Damons
Dr Osayande Evbuomwan is a Senior Lecturer and medical specialist in nuclear medicine in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS).
The University of the Free State (UFS) Department of Nuclear Medicine has, for the first time, started using Lutetium 177 PSMA (Lu-177 PSMA) therapy for the treatment of metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer.

The UFS and the Free State province are now joining other South African universities, such as the University of Pretoria, the University of the Witwatersrand, and other provinces in using this method to treat MCRPC patients. 

Dr Osayande Evbuomwan, a Senior Lecturer and medical specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, says they have started treating their first MCRP patient (first cycle) with peptide receptor radionuclide therapy (PRRT) on 15 July. It is the first time that Lutetium 177 PSMA – a type of PRRT used for treating patients with MCRPC – has been used in the Free State. This method is used on MCRPC patients who are not eligible for chemotherapy or have failed first- or second-line chemotherapy.

Expertise and funds are now available for this treatment

Dr Evbuomwan was trained and exposed to this therapy at the University of the Witwatersrand during his registrar training in nuclear medicine. When he joined the UFS in 2019, he – with the always available help of the Head of Department, Dr Gerrit Engelbrecht – pushed for the therapy to be used in the department. 

“We in the Department of Nuclear Medicine are happy that expertise is now available and that some funds have been released for this treatment to commence. The index patient is very sick with MCRPC and was too sick to qualify for first-line chemotherapy. Each patient will need about four-six cycles for complete treatment. The patient is being treated in the Department of Nuclear Medicine at the Universitas Academic Hospital and Annex.” 

“We are hoping that he will be able to complete at least four cycles and respond well to the treatment. We believe that the ability to administer this treatment now is good news for the Free State, as the people of the Free State also deserve to be exposed to this level of treatment. We are hoping that the government will continue to provide more funds for more of these patients to be treated in our facility,” says Dr Evbuomwan.

It was budgeted to treat five patients (20 cycles), with each cycle (just the Lu-177 PSMA) costing more than R50 000. 

A googled image from the internet of a case before, during, and after completing the full course of therapy. The first image is before
treatment and the last image is after completing treatment, while the images in between are during treatment. (Source: Google) 

Prostate cancer one of the leading causes of morbidity and mortality

Dr Evbuomwan says prostate cancer is one of the leading causes of morbidity and mortality in the world, including South Africa. When it progresses to the advanced stage of MCRPC, the prognosis becomes bad. 

Dr Evbuomwan explains that there are various conventional systemic therapies, including first- and second-line chemotherapy that could be used to treat patients at this bad stage. However, not all patients are fit for chemotherapy. The few who are fit, according to Dr Evbuomwan, usually end up failing the first-line chemotherapy, which has a lot of undesirable side effects and require long-stay hospital admissions. 

Only a few centres are able to offer second-line chemotherapy. So many of these patients end up suffering from prolonged bone pains before eventually dying from the disease.

PRRT is a targeted nuclear medicine therapy that offers the opportunity to deliver very high levels of radiation specifically to cancer cells, because these cancer cells express specific receptors to which certain peptides can bind. This specificity to cancer cells offers the advantage of providing lower doses of radiation and damage to normal organs and tissues, a characteristic that conventional therapies do not offer, explains Dr Evbuomwan.  

According to him, Lutetium 177 PSMA (Lu-177 PSMA) is a type of PRRT used for treating patients with MCRPC, who are not eligible for chemotherapy or have failed first-line chemotherapy. Numerous research studies around the world have proven that this treatment improves quality of life, slows down disease progression, and improves overall survival, with little or very tolerable side effects in most patients. 

The University of Pretoria is one of the pioneers of this treatment in the world, having done a lot of research with it since 2017. Other provinces such as the Western Cape and KwaZulu-Natal have also recently become involved with the therapy. This therapy is expensive and requires a lot of expertise. It also involves the input of a multidisciplinary team (MDT), which must at least include a nuclear medicine physician, a radiation oncologist, and a urologist. The Departments of Urology and Radiation Oncology at the UFS were also instrumental in the initiation of the therapy and form part of the MDT team at the UFS in the management of these patients.

Treatment puts department, university, and hospital on the map

Dr Evbuomwan says the ability to administer this treatment puts the department, the UFS, and the hospital on the map, alongside other top universities within and outside the country. “It also creates an avenue for us to gather data for research purposes and for publications. We are now able to offer a promising, safe, and highly efficacious therapy for patients with MCRPC in the Free State. Some of these patients no longer need to travel to other provinces to get the treatment.”

There are plans to expand the treatment to more patients – and hospital management, who were present at the first treatment, are excited and looking forward to the outcome of this current treatment.

Watch video below:

News Archive

Postgraduates’ new Kovsies home
2013-05-10

 
Some of the guests attending the launch, included from left: Prof Driekie Hay, Vice-Rector: Academic, Dr Henriette van den Berg, Director: Postgraduate School and Prof Corli Witthuhn, Vice-Rector: Research.
10 May 2013
Photo: Johan Roux

Postgraduate students and their academic 'parents' at the University of the Free State (UFS) now have a dedicated physical, emotional and electronic space to provide for their specialised needs in order to further promote research excellence at the UFS.

The university's Postgraduate School was launched in May 2011, but ventured further in the quest to fulfil and expand its mandate with new initiatives. These different aspects of the school were launched on Wednesday 8 May 2013 in the CR Swart Auditorium on the Bloemfontein Campus. The postgraduate strategy, postgraduate prospectus, the website and the headquarters of the Postgraduate School in the Johannes Brill Building were all unveiled and launched.

Prof Driekie Hay, Vice-Rector: Academic, who was a major driving force behind the formation of the Postgraduate School, during her address at the opening emphasised the multifaceted and unique relationships which often exist between students and supervisors.

Prof Hay, who has a distinguished academic background in postgraduate teaching, made plain her expectations for the Postgraduate School. She said it aims to "create an intellectual space for postgraduate students and supervisors" in order to produce world-class intellectuals at this university.

She said the school will empower both students who often don't know what to expect from supervision, as well as supervisors who often lack supervision skills. Through this it will be possible to create healthy, productive relationships between the distinct pairs in often misunderstood, unbalanced and intricate interactions.

Dr Henriette van den Berg, Director of the Postgraduate School, introduced the strategic plan of the school and emphasised the great strides that have already been made and what still needs to be done at the UFS in terms of postgraduate teaching. According to her, the Postgraduate School aims towards "holistic development of postgraduate students with transferable skills," through a multi-level and institution-wide approach at the university.

"Our aim is to develop a one-step service for postgraduate students, involving all the different stakeholders," she said.

The new Postgraduate School website was also showcased during the event. Reachable through a number of avenues on the main website, the site offers a digital version of the Johannes Brill Building. Brimming with features catering specifically for local, international, current and prospective students, the website provides crucial information.

The Johannes Brill Building's refurbished interior, with staff offices, seminar rooms and social spaces, were also showcased to UFS' staff and students. The initial phase of the Supervisors' Wall of Fame was also unveiled. According to Dr van den Berg , the wall will after completion bestow much-deserved praise on a hand-picked group of 60 supervisors who have respectively been responsible for more than 300 and more than 500 successful PhD and master's candidates over the past decade.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept